Retinoid inhibition of expression of VEGF
US6001885A · kind A · utility
80Cited by
1References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 2, 1997 |
| Grant date | Dec 14, 1999 |
| Priority date | — |
| Expiry date | Sep 2, 2017 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The retinoids, in particular the anti-AP-1 retinoids, effectively inhibit the expression of VEGF, and thus are useful for the therapeutic treatment of disease states manifesting an overexpression of VEGF.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.